SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Clinical trial NCT07307287 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07307287
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

SHR-A1811 HER2-Postive Breast Cancer HR+ Breast Cancer Early Breast Cancer Locally Advanced Breast Cancer

Start date: 2025-12-20
Primary completion: 2027-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.